GlassScriptPhysician profile
Albert A Lagomarsini
NPI 1114116902
$1,677.12
in general payments reported to CMS, 2019-2025
10 companies · $257 in 2025
The $257 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2021: $155 · 2022: $176 · 2023: $668 · 2024: $307 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,155 · Entertainment: $78.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,154.81 |
| Entertainment | $78.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $926.53 | 2022-2025 | Infuse, Ultra Multifocal Toric |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.00 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $116.98 | 2023 | Acuvue |
| Aerie Pharmaceuticals, INC. | $112.92 | 2019 | |
| Coopervision INC. | $112.70 | 2021-2025 | Misight Contact Lens, Clariti Contact Lens |
| Optos, INC. | $78.12 | 2024-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Abbvie INC. | $70.62 | 2022-2023 | |
| Alcon Vision LLC | $64.94 | 2025 | Clareon |
| Carl Zeiss Meditec USA, INC. | $49.93 | 2024 | Cirrus Hd-Oct |
| Biotissue Holdings INC. | $19.38 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Lagomarsini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.